Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents + Neuronavigation-guided single-element focused ultrasound transducer + Positron Emission Tomography (PET) + FLORBETAPIR F-18 + PERFLUTREN

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents + Neuronavigation-guided single-element focused ultrasound transducer + Positron Emission Tomography (PET) + FLORBETAPIR F-18 + PERFLUTREN
Treatment and conditionWhere it standsTrials
Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents + Neuronavigation-guided single-element focused ultrasound transducer + Positron Emission Tomography (PET) + FLORBETAPIR F-18 + PERFLUTREN for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1